Study Group: HCV Gastroenterologists (US)(?)
Council Members in this Study Group: 60
Request a survey with this Study Group
Leading Experts in this Study Group
Hepatologist and Gastroenterologist
Miami Gastroenterology Consultants PA
Miguel Rodriguez, MD, is a Hepatologist & Gastroenterologist, Managing Partner of Miami Gastroenterology Consultants, PA., a single specialty group in Miami, Florida. He is former Assistant Professor of Medicine of the University of Miami School of Medicine and Center for Liver Diseases and Division...
Professor of Clinical Medicine
University of Miami School of Medicine
Christopher O'Brien, MD, is Professor of Clinical Medicine in the Hepatology Division at the University of Miami Miller School of Medicine, Florida. Dr. O'Brien has been published numerous times and has extensive research experience in Hepatitis B and C. He is a member of the American Gastroenterology...
Associate Professor of Clinical Medicine
Georgetown University - CC
Averell Sherker, MD, FRCP, is Director of the Center for Liver Diseases at Washington Hospital Center in Washington, DC. He is also Associate Professor of Clinical Medicine at Georgetown University. Previously, Dr. Sherker was Director of Hepatology Research at the McGill University in Canada, where...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Gastroenterologists (US) | 820 |
| Physicians who Treat HCV (US) | 90 |
| Physicians who Treat GERD (US) | 359 |
| Gastroenterologists who Treat GERD | 367 |
| Hepatologists (US) | 84 |
| IBD Gastroenterologists (US) | 167 |
| Gastroenterologists in Private Practice (US) | 196 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
In the two large phase 3 registration trials of albinterferon alfa-2b (Albuferon, Human Genome Sciences), called ACHIEVE-1 and ACHIEVE-2/3, several patients in the arm using Albuferon 1200 mcg per 2 weeks + RBV were found to have serious pulmonry adverse events. Such serious events were not...
IDEAL study shows equivalent efficacy of Ribavirin + PEG-Intron 1.5 vs. 1.0 mcg/kg vs. Pegasys for HCV genotype 1
The IDEAL study compared combination therapy of ribavirin (RBV) plus PEG-Intron (Schering) at 1.5 mcg/kg weekly vs. 1.0 mcg/kg vs. Pegasys (Roche) 180 mcg weekly in treatment-naive HCV genotype 1 patients. The primary outcome of SVR rate was similar: 40% vs. 38% vs. 41%. ...
Hepatitis C: little-recognized nitazoxanide (Alinia, Romark) shows remarkable activity in combination therapy for HCV genotype 4
A phase 2 study in Egypt of hepatitis C genotype 4 showed that the viral cure or SVR rate (here actually SVR12 = %HCV RNA negative at post-Rx week 12, real SVR is at week 24) is much improved when nitazoxanide is added to standard therapy. SVR12 was 79% in nitazoxanide + Pegasys + ribavirin...
First announcement of data (very limited) from InterMune's HCV protease inhibitor ITMN-191
In the phase 1a (single ascending dose, SAD) trial, ITMN-191 was found to be safe in the first doses tested, and more cohorts will be tested with higher doses. Details of the study will be presented later in quarter 1 of 2008. Multiple ascending doses (MAD) in a 2-week monotherapy phase...
New Pharmasset/Roche HCV polymerase inhibitor R7128 is promising in combination therapy
In this small pilot study, R7128 at 1500 mg twice daily combined with Pegasys + ribavirin led to a rapid viral response (HVC RNA <15 IU/mL at week 4) in 85% of patients compared with 35% at 500 mg twice daily and 10% with Pegasys + ribavirin alone. R7128 did not add much toxicity...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Government/Military Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
- Other Freestanding Healthcare Facility
- Private/For-Profit Healthcare Research Entity
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Medical Director
- Physician - Department Chair
- Assistant Professor
- Partner